Said Hines. ‘This is not a panacea, it is the first step in establishing a long-term issue , this law is not specifically smokers, it is the orientation of their children and grandchildren.
An oral cell cycle regulator is in various phase 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, Forward Looking Statementsadvanced cancers. EntreMed objective is to develop and marketing of new compounds on the company’s expertise in angiogenesis, cell cycle regulation and inflammation of the base – processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the company website at and in various filings with the Securities and Exchange Commission are available.. Continue reading